Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 82653 refers to a laboratory test that quantitatively measures the level of pancreatic elastase (EL-1) in fecal samples. Pancreatic elastase is a glycoprotein digestive enzyme produced by the acinar cells of the pancreas. Its primary function is to aid in the digestion of food by breaking down proteins, which facilitates the absorption of essential nutrients in the intestine. Additionally, pancreatic elastase plays a role in the transport of cholesterol by combining with bile acids and neutral steroids. The fecal test for EL-1 is particularly useful in assessing pancreatic function, especially in patients diagnosed with cystic fibrosis. This test can also help in diagnosing or ruling out conditions associated with pancreatic exocrine insufficiency, such as chronic pancreatitis, pancreatic tumors, cholelithiasis, and diabetes mellitus. Prior to conducting the test, it is essential to discontinue any pancreatic enzyme supplements to ensure accurate results. A sample of formed stool is collected in a clean container, and the analysis is performed using the enzyme-linked immunosorbent assay (ELISA) method. For a quantitative assessment of pancreatic elastase levels, the appropriate code to report is 82653, while 82656 should be used for qualitative or semi-quantitative tests that only determine the presence of EL-1.
© Copyright 2026 Coding Ahead. All rights reserved.
The fecal test for pancreatic elastase (EL-1) is indicated for several clinical scenarios, particularly in the evaluation of pancreatic function. The following conditions may warrant the use of this test:
The procedure for conducting the fecal test for pancreatic elastase involves several key steps to ensure accurate results. First, it is essential to prepare the patient by advising them to discontinue any pancreatic enzyme supplements prior to the test. This step is crucial as it helps to avoid interference with the test results. Next, a sample of formed stool must be collected in a clean container. The collection should be done carefully to ensure that the sample is not contaminated, as this could affect the accuracy of the test. Once the sample is obtained, it is sent to the laboratory for analysis. The laboratory utilizes the enzyme-linked immunosorbent assay (ELISA) method to quantitatively measure the level of pancreatic elastase present in the fecal sample. This method is sensitive and specific, allowing for reliable quantification of the enzyme. The results of the test will indicate the amount of pancreatic elastase in the feces, which can then be interpreted in the context of the patient's clinical condition.
After the fecal test for pancreatic elastase has been completed, there are no specific post-procedure care requirements for the patient. However, it is important for healthcare providers to communicate the expected timeline for receiving test results, which can vary depending on the laboratory's processing times. Patients should be informed that the results will be used to assess pancreatic function and may influence further diagnostic or therapeutic decisions. If the test indicates low levels of pancreatic elastase, additional evaluations or interventions may be necessary to address any underlying conditions affecting pancreatic health.
| Short Descr | EL-1 FECAL QUANTITATIVE | Medium Descr | ELASTASE PANCREATIC FECAL QUANTITATIVE | Long Descr | Elastase, pancreatic (EL-1), fecal; quantitative | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | Q4 | Service for ordering/referring physician qualifies as a service exemption | 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | GZ | Item or service expected to be denied as not reasonable and necessary | PD | Diagnostic or related non diagnostic item or service provided in a wholly owned or operated entity to a patient who is admitted as an inpatient within 3 days |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2022-01-01 | Added | Code added |
Get instant expert-level medical coding assistance.